Postpartum Depression vs. Baby Blues: How to Tell Them Apart

Almost every new parent cries in those first days. Almost every one of them wonders, at some point, whether this is normal. It is, most of the time. And the answer to that question depends on one thing above everything else: the pattern of what you feel, and whether it is getting better or getting worse.

Baby blues and postpartum depression are not two points on the same spectrum. They are different conditions with different biological drivers, different timelines, and different implications for care. Understanding the distinction is not just clinically useful. It is the difference between resting at home with support and starting treatment before symptoms compound.

What This Page Covers

• The biology behind baby blues and why they resolve on their own
• What makes PPD clinically distinct
• The symptoms that cross the line, and when to contact a provider
• The Edinburgh Postnatal Depression Scale, the primary screening tool
• Every treatment option, including two FDA-approved medications specifically for PPD
• Why the gap between postpartum appointments matters for recovery

Baby Blues: A Normal Neurobiological Response

Baby blues are not weakness. They are your brain responding to one of the fastest hormonal changes the human body undergoes.

During pregnancy, estrogen and progesterone rise steadily and reach their highest levels, supporting fetal development and stabilizing mood. Within 24 to 48 hours after delivery, these hormone levels drop dramatically, creating a biochemical shift that can contribute to feelings of sadness, irritability, and anxiety. This drop is predictable, nearly universal, and not a sign that something has gone wrong.

Up to 80% of new mothers, or up to 4 in 5 birthing parents, experience symptoms of the baby blues. Symptoms typically begin 2 to 3 days after birth, peak somewhere in the first week, and resolve on their own within 2 weeks. Common signs include:

• Sudden tearfulness without an obvious cause
• Mood swings, sometimes within the same hour
• Irritability and low patience
• Trouble sleeping even when the baby is resting
• Feeling overwhelmed or emotionally raw

The essential feature of baby blues is that they are mild and self-limiting. You may feel tender or weepy, but you can still care for yourself and your baby. The feelings come and go. Support, rest, and time are typically sufficient.

Postpartum Depression: A Different Condition

Postpartum depression is not a more severe version of baby blues. It is a clinically separate condition with different drivers and a different trajectory.

PPD is a type of depression that causes intense feelings of sadness, anxiety, or despair that keep people from being able to do their daily tasks. Unlike baby blues, it does not resolve on its own and often worsens without clinical attention.

PPD most commonly starts about 1 to 3 weeks after childbirth but can occur any time within the first year. It affects approximately 1 in 8 women who give birth, according to CDC data.

Symptoms of PPD include everything that can appear in baby blues, plus:

• Persistent sadness or emotional numbness most of the day, most days
• Difficulty bonding with or feeling connected to your baby
• Intrusive or distressing thoughts
• Significant changes in appetite or sleep beyond what newborn care explains
• A persistent sense of hopelessness or worthlessness
• Withdrawal from family and friends
• Trouble completing basic daily tasks
• Thoughts of harming yourself or your baby

That last point is urgent. If you are having thoughts of harm to yourself or your baby, call 911 or go to the nearest emergency room immediately. The maternal mental health hotline (1-833-943-5746) is available 24 hours a day, 7 days a week.

A Side-by-Side Comparison

Feature	Baby Blues	Postpartum Depression
Onset	Days 2 to 3 after birth	1 to 3 weeks after birth, up to 1 year
Duration	Resolves within 2 weeks	Persists beyond 2 weeks, often months without treatment
Severity	Mild, comes and goes	Persistent, often worsening
Daily functioning	Able to care for self and baby	Basic tasks become difficult or impossible
Bonding	Generally intact	Often impaired
Needs treatment	Rest and support	Clinical evaluation; usually therapy and/or medication

The Two-Week Mark: Useful, Not Absolute

The 2-week threshold is the most widely cited guide for distinguishing baby blues from PPD. It is clinically useful. But it is not the complete picture.

Direction matters as much as duration. Symptoms that are worsening across the first two weeks, rather than easing, are worth taking seriously even before the two-week mark passes. If symptoms of baby blues do not ease up after 2 weeks, contact your doctor right away. Do not wait for your 6-week checkup.

Functional impairment is a threshold regardless of timing. If you are struggling to care for your baby, eat, or maintain basic hygiene, those are clinical signals that do not need to wait for a calendar date.

Any thought of harm is an emergency. Intrusive thoughts of harm at any point are an immediate reason to contact a provider or call 911.

How PPD Is Diagnosed: The Edinburgh Postnatal Depression Scale

When a prescriber or OB screens for PPD, the primary tool is the Edinburgh Postnatal Depression Scale (EPDS). It is a 10-item self-report questionnaire that asks how you have felt over the past 7 days, covering sad mood, anxiety, feelings of guilt, sleep difficulty, and thoughts of self-harm. Each item scores 0 to 3; the total ranges from 0 to 30.

The EPDS is the most widely used postpartum depression screening tool in the world, recommended by both the US Preventive Services Task Force and ACOG for pregnant and postpartum women. A score of 10 or higher is the standard clinical threshold for further evaluation.

A 2020 systematic review and individual participant data meta-analysis of 58 studies and more than 15,000 participants found that combined sensitivity and specificity was maximized at an EPDS cutoff of 11 or higher, with no significant difference in accuracy between pregnant and postpartum women. At a cutoff of 10 or higher, sensitivity was 0.85 and specificity was 0.84.

A positive EPDS score is not a diagnosis. It is a prompt for a fuller clinical evaluation covering symptom timeline, functional impact, and ruling out thyroid dysfunction or other conditions with similar presentations.

Risk Factors That Warrant Closer Monitoring

Some women face higher risk of PPD and benefit from earlier, more frequent screening:

• Personal or family history of depression, anxiety, or bipolar disorder
• Prior episode of PPD with an earlier pregnancy
• Stressful pregnancy events, including preeclampsia, gestational diabetes, or a NICU admission
• Limited social support or relationship strain
• History of significant mood changes with the menstrual cycle
• Difficult or traumatic birth experience

Changes in hormone levels, including a history of mood symptoms associated with menstruation, are a recognized risk factor for PPD. Women who notice significant mood shifts tied to hormonal changes may be more vulnerable to the postpartum hormonal drop.

PPD Is Not Limited to Birthing Mothers

Non-birthing partners can develop postpartum depression, with estimates of 4 to 10% among fathers in the first year. The same risk factors apply: personal history of depression, relationship strain, sleep deprivation, and financial stress. A partner showing persistent sadness, withdrawal, or irritability after the baby arrives deserves clinical attention.

Treatment Options for PPD

Once PPD is identified, effective care exists across a range of severity levels.

Psychotherapy

Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) are the evidence-based first-line treatments for mild to moderate PPD. CBT helps recognize and change negative thought patterns. IPT addresses relationship dynamics and the transition into a new parenting role. Both show strong outcomes for PPD across multiple clinical trials.

SSRIs

Sertraline is the most commonly prescribed SSRI for PPD in breastfeeding mothers because it has the lowest concentration in breast milk among the commonly used options. SSRIs require 4 to 6 weeks to reach full therapeutic effect. All prescribing during the breastfeeding period should involve a clinical conversation about individual risk and benefit.

FDA-Approved PPD-Specific Medications

Two medications are now approved specifically for PPD, operating through a different mechanism than SSRIs:

Brexanolone (Zulresso), approved March 2019: A neuroactive steroid that acts on GABA receptors. Administered as a continuous 60-hour IV infusion in a clinical setting, brexanolone was the first medication approved specifically for PPD. Its mechanism addresses the neurosteroid deficit following the postpartum hormone drop, distinct from SSRI serotonergic action.

Zuranolone (Zurzuvae), approved August 2023: The first oral medication approved for PPD. Taken once daily at home for 14 days. In double-blind, randomized, placebo-controlled clinical trials, zuranolone demonstrated rapid, statistically significant, and clinically meaningful improvements in depressive symptoms, with benefits in some patients beginning as early as day 3. Secondary analyses also found improvements in anxiety, insomnia, and functional health.

SSRIs remain the most commonly prescribed pharmacotherapy for PPD given their accessibility and long safety record in the breastfeeding period. The PPD-specific medications are most relevant for severe presentations or when SSRIs have not provided adequate response.

The Monitoring Gap

One of the most consistent gaps in PPD care is what happens between delivery and the 6-week checkup. Symptoms can escalate quickly in those weeks. Fear of stigma, uncertainty about whether what you are feeling is serious enough, and the gap between appointments all mean that many women do not get clinical attention until symptoms have already compounded.

Daily check-ins that reach a licensed prescriber fill that gap. For mothers managing PPD alongside medication, it means side effects and response signals are caught in days, not months, and adjustments happen before a developing problem deepens.

“Postpartum depression is among the most undertreated conditions I see, not because care does not exist, but because the screening gap and stigma keep women from disclosing until symptoms have already compounded,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “A care model that normalizes checking in between visits removes both barriers. The clinical data is there, and I can act on it quickly.”

For more on how long PPD lasts and what shortens recovery, read our guide on how long postpartum depression lasts. To start care with a licensed prescriber, begin your anonymous intake with SiggyMD.

What Members Are Saying

L.M., 32

Postpartum Depression

“I kept telling myself it was baby blues and that it would pass. By week four I still could not get out of bed without crying. When I was finally honest with my OB about how I was really feeling, she said my EPDS score at my two-week visit had already flagged something. I just had not told her the full picture. Getting treatment changed everything.”

A.N., 29

Postpartum Depression with Anxiety

“For me it was not sadness. It was the anxiety. I could not stop cycling through worst-case scenarios for my daughter. Nothing about baby blues described that. My prescriber screened me, started me on sertraline, and connected me with a therapist. Six weeks later I was actually present in a way I had not been.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

Sources

1. American College of Obstetricians and Gynecologists. Postpartum Depression. Reviewed 2023.

2. StatPearls / NCBI Bookshelf. Perinatal Depression. Updated 2024.

3. Centers for Disease Control and Prevention. Depression Among Women. Accessed June 2026.

4. UPMC HealthBeat. Postpartum Depression vs. Baby Blues: Understanding the Key Difference. Reviewed by Jocelyn Jane Fitzgerald, MD. June 2025.

5. WebMD. Postpartum Depression: How It Differs From the Baby Blues. Reviewed February 2025.

6. Levis B, Negeri Z, Benedetti A, et al. Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum women: systematic review and meta-analysis of individual participant data. BMJ. 2020;371:m4022.

7. Hou S, et al. Screening for Perinatal Depression: Barriers, Guidelines, and Measurement Scales. J Clin Med. 2024.

8. Deligiannidis KM, Giannopoulos A, Singh J. Clinical Utility of Zuranolone for Postpartum Depression: A Narrative Review. Neuropsychiatric Disease and Treatment. 2025;21:93-105.

9. Thompson JF, et al. Neurosteroids and Postpartum Depression: Brexanolone and Zuranolone. Cureus. 2023.

10. Cleveland Clinic. Postpartum Depression (PPD): Causes, Symptoms & Treatment. Updated 2026.

11. American Dental Association. Postpartum Blues vs Postpartum Depression. Accessed June 2026.

12. Akram AS, et al. Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression. Clinical Therapeutics. 2024.